IMPE Abstracts

Over the last two decades, there has been a major expansion in agents targeting contributors to metabolic dysfunction in type 2 diabetes. Modern pharmacologic agents have allowed clinicians to move beyond reduction in glycemia as the primary treatment target and to begin to select agents based on more individualized aspects of dysfunction unique to each patient. The potency of this approach is demonstrated by the changing outcomes landscape for adult individuals with type 2 di...